Survival benefit of patients with early-stage ovarian carcinoma treated with paclitaxel chemotherapeutic regimens / 부인종양
Journal of Gynecologic Oncology
;
: e16-2018.
Article
Dans Anglais
| WPRIM
| ID: wpr-740168
ABSTRACT
OBJECTIVE:
Adjuvant chemotherapy was introduced in patients with early-stage ovarian cancer (OC). The benefit of standard chemotherapeutic regimens including taxane has not been established.METHODS:
Patients with early-stage OC from the National Health Insurance Research database of Taiwan who received platinum plus cyclophosphamide (CP) or platinum plus paclitaxel (PT) for 3–6 cycles were recruited, and the disease-free survival (DFS) and overall survival (OS) were determined.RESULTS:
A total of 1,510 early-stage OC patients, including 841 who received CP regimen and 699 who received PT regimen, were included. The 2 groups had a similar estimated probability of 5-year DFS (PT vs. CP, 79.0% vs. 77.6%; p=0.410) and OS (84.6% vs. 84.3%; p=0.691). Patients >50 years of age who received the CP regimen had a lower 5-year DFS than the patients ≤50 years of age who received the CP (p50 years of age who received the CP regimen had a worse 5-year OS compared with the other 3 groups (p=0.019) (p=0.179 for patients >50 years of age in the PT group; p=0.002 for patients ≤50 years of age in the CP group; and p=0.061 for patients ≤50 years of age in the PT group). Patients with the CP or PT regimen for 3–5 cycles had a similar 5-year DFS and OS compared to 6 cycles (p>0.050).CONCLUSION:
Chemotherapeutic regimens with taxane could be recommended for early-stage OC patients >50 years of age.
Texte intégral:
Disponible
Indice:
WPRIM (Pacifique occidental)
Sujet Principal:
Tumeurs de l'ovaire
/
Platine
/
Taïwan
/
Traitement médicamenteux adjuvant
/
Paclitaxel
/
Survie sans rechute
/
Cyclophosphamide
/
Traitement médicamenteux
/
Programmes nationaux de santé
Limites du sujet:
Humains
Pays comme sujet:
Asie
langue:
Anglais
Texte intégral:
Journal of Gynecologic Oncology
Année:
2018
Type:
Article
Documents relatifs à ce sujet
MEDLINE
...
LILACS
LIS